Kodu・Aktsiate loetelu・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Avatud

SektorTervishoid

48.37 -1.31

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

48.46

Max

49.68

Põhinäitajad
By Trading Economics
Sissetulek	-56M -58M
Müük	11M 219M
Aktsiakasum	0.39
Kasumimarginaal	-26.646
Töötajad	778
EBITDA	-50M -30M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+32.98% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	3. nov 2026

Turustatistika
By TradingEconomics
Turukapital	79M 2.8B
Eelmine avamishind	49.68
Eelmine sulgemishind	48.37

Uudiste sentiment

By Acuity

75%

25%

316 / 340 Pingereas Healthcare

Supernus Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. aug 2026, 19:36 UTC

Supernus Pharmaceuticals Inc is trading higher, maintaining upward momentum since Monday. The stock remains above its 20-day moving average and near a one-month high.

17. aug 2026, 19:26 UTC

News

Supernus Pharmaceuticals Inc is featured in a cautionary analysis from Yahoo Finance, citing below-average sales growth and declining cash flow margin. The stock is roughly flat today.

14. aug 2026, 19:16 UTC

Macro Event

Supernus Pharmaceuticals Inc shares are higher, maintaining momentum since Thursday amid broader market caution following a decline in U.S. retail sales.

13. aug 2026, 19:16 UTC

Supernus Pharmaceuticals Inc shares are lower Thursday, pulling back from an early high. No specific news was identified to explain the movement.

12. aug 2026, 19:51 UTC

Supernus Pharmaceuticals shares are higher amid positive market sentiment following an inflation report and strength in technology stocks.

11. aug 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower as the Pharmaceuticals sector declines. The stock is trading with unusually high volume today.

10. aug 2026, 22:46 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Monday's close amid broader market reassessments of interest rate hikes.

7. aug 2026, 19:31 UTC

Supernus Pharmaceuticals Inc. is trading higher, influenced by an advancing overall market amid positive macroeconomic indicators, despite ongoing geopolitical tensions.

6. aug 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday's close, amid unusually high market volume.

5. aug 2026, 20:03 UTC

Supernus Pharmaceuticals Inc shares are higher Wednesday, driven by high market volume and broader positive sentiment amid declining oil prices and geopolitical optimism.

4. aug 2026, 19:51 UTC

News

Supernus Pharmaceuticals is declining following its merger announcement with Indivior and a quarterly revenue report of $219 million amid a net loss of $58 million.

3. aug 2026, 19:51 UTC

Social Media

News

Event

Supernus Pharmaceuticals announced a merger with Indivior, creating a company with $2.2 billion in revenue. Shares are higher following strong Q2 earnings that beat estimates.

31. juuli 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early gain amid broader market concerns over rising Treasury yields and crude oil prices.

30. juuli 2026, 14:33 UTC

Supernus Pharmaceuticals Inc. shares are lower, impacted by weakness in the pharmaceuticals sub-sector. The stock briefly rebounded earlier in the session before declining.

29. juuli 2026, 17:26 UTC

Supernus Pharmaceuticals Inc. shares are lower today amid volatility, with no specific news identified. The stock remains below its 20-day moving average.

28. juuli 2026, 17:06 UTC

Supernus Pharmaceuticals Inc. shares are higher today, recovering from an earlier decline. The stock remains near the lower end of its one-month trading range.

27. juuli 2026, 20:06 UTC

Supernus Pharmaceuticals Inc shares are higher Monday, despite earlier gains pulling back. Market dynamics reflect a significant decline in oil prices and inflation reassessment.

24. juuli 2026, 19:06 UTC

Supernus Pharmaceuticals Inc. shares are lower today, following an early peak, amid broader market dynamics influenced by a pullback in crude oil prices.

20. juuli 2026, 20:06 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early high amid a broader market decline during the session.

Võrdlus sarnastega

Hinnamuutus

Supernus Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

32.98% tõus

12 kuu keskmine prognoos

Keskmine 65.2 USD 32.98%

Kõrge 67 USD

Madal 63 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Supernus Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Supernus Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

316 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.